SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the token's vision of merging cryptocurrency with green culture, emphasizing growth, freedom, and innovation within the digital space. Discussions highlight Weedcoin as more than just a digital currency, but as a symbol of a cultural movement and a key to unlocking future opportunities. The community expresses strong conviction and promotes Weedcoin as a force that shapes the digital landscape.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reported record-high monthly and quarterly delivery numbers, sparking enthusiasm about the company's growth. Community discussions revolve around the significant year-over-year increase in deliveries and the potential impact of new models like Onvo and Firefly. Some investors express optimism about NIO's future, while others focus on its valuation relative to competitors in the EV sector.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending after reports of a U.S. government equity stake, signaling strong support for domestic lithium production. The community is buzzing about a potential short squeeze and the stock's long-term prospects, drawing comparisons to government-backed runs of $MP and $INTC. Investors view this as a bullish sign for the company's Thacker Pass project and its role in securing the U.S. lithium supply chain.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as a government shutdown looms, triggering volatility and uncertainty. Community members are debating whether the shutdown is already priced in, with some anticipating a potential dip while others expect a market rally similar to past shutdowns. Overall sentiment is mixed, with both bullish and bearish arguments circulating, focusing on historical patterns and potential economic impacts.

Aventus Network

Aventus Network ($AVT.X) is trending due to its strong chart setup, real-world partnerships (Vodafone, Heathrow Airport, Polkadot) and potential for a breakout. Community members believe the token is undervalued, highlighting its low market cap and integration with Polkadot as catalysts for significant upside. Traders are closely monitoring volume as a key indicator for potential price movement.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to earnings, with community chatter focused on revenue growth and turnaround efforts despite tariff concerns. Discussions include both bullish and bearish outlooks, with some anticipating a move towards $80 while others foresee a drop. The brand's collaboration with SKIMS and the impact of global factors like China sales and potential government shutdowns are also being closely monitored.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, creating market uncertainty. The community is debating the potential impact, with some anticipating a pullback while others believe a deal will be reached, leading to a rally. Discussions also involve broader market dynamics, such as the influence of a few mega-cap stocks and end-of-quarter window dressing.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to recent unaudited financial results showing positive EPS, sparking discussions about its low float and potential for a short squeeze. The community is actively watching key resistance levels and anticipating further upward movement. Some traders highlight the possibility of a share offering and caution around the stock's historical volatility and association with Chinese companies.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is gaining traction as users express bullish sentiment and encourage community growth, with some highlighting potential influencer support. Community members are rallying around the meme coin, urging others to "RAGE harder" and join the movement.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding a potential government shutdown and related political tensions, particularly concerning healthcare and immigration policies. Community members are debating the implications of the shutdown and its impact on various sectors, with some expressing concerns about potential economic consequences. Others are focused on political affiliations and perceived motivations behind the shutdown, reflecting broader ideological divides.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amgen (AMGN) on Friday announced a $650 million expansion of its U.S. manufacturing network, on the heels of President Trump’s latest pharmaceutical tariff announcement.Trump said in a post on Truth Social on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1 unless manufacturers are actively building plants in the country.Amgen <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs">said</a> on Friday that the planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos, Puerto Rico. The investment is also expected to create about 750 jobs, including construction roles and skilled manufacturing jobs. According to Amgen, the company has invested more than $40 billion in U.S. manufacturing and research and development since late 2017.Earlier this year, the company announced a $900 million expansion of its Ohio manufacturing facility, which followed a late-2024 announcement of a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_54_57_PM_png_99b99c433b.webp" alt="AMGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="62"><figcaption>AMGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>Jefferies analyst Akash Tewari stated on Friday that Trump’s tariffs may not have a material impact on pharmaceutical companies, as several large-cap pharmaceutical firms have already announced plans to establish U.S. manufacturing facilities.A Stocktwits user echoed the analyst’s sentiment, stating that Amgen will also likely be unaffected by the tariffs.<stembedurl>https://stocktwits.com/BobBijawklah/message/630132763</stembedurl>AMGN stock is up 4% this year and down by about 15% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bioaffinity-technologies-stock-surge-over-cypath-lung-case-studies/chDVjeMR3ea">bioAffinity Technologies Stock Surged A Whopping 79% Today – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement

Amgen said that the planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos, Puerto Rico.

Equity

Amgen said that the planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos, Puerto Rico.


Uber Technologies (UBER) reportedly expects faster-than-expected growth for its grocery and retail delivery segment. &nbsp;Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-26/uber-sees-non-takeout-deliveries-becoming-12-5-billion-business?srnd=homepage-americas">reported</a> on Friday, citing a company spokesperson, that Uber expects non-restaurant deliveries to hit an annual run rate of $12.5 billion in gross bookings by the end of 2025. This marks a growth of over 25% from the $10 billion run rate the company shared earlier this year in May, the report added. &nbsp;<a href="https://stocktwits.com/symbol/UBER">UBER shares</a> traded flat at the time of writing. On Stocktwits, retail sentiment regarding UBER stock shifted from ‘neutral’ to ‘bearish’ territory over the past 24 hours.In the second quarter, Uber’s delivery segment saw a 20% increase in gross bookings to $21.7 billion, while revenue jumped 25% to $4.1 billion. In fact, in the second quarter, the delivery segment accounted for nearly half of the company’s gross bookings.However, CEO Dara Khosrowshahi said in August that Uber still has “a long runway to drive further adoption” in delivery, noting that 75% of its rideshare customers have not tried ordering grocery and retail goods from the Uber app, as reported by Bloomberg.Rebecca Payne, group product manager for grocery and retail, told Bloomberg that 6 p.m. on Sundays is the peak time for grocery orders on Uber, and the most popular items are bananas, limes, lemons, cucumbers, Hass avocados, and red Roma tomatoes. More updates about the business are expected at the annual Groceryshop conference in Las Vegas on Sunday, the report added.In the past few months, Uber has announced partnerships or collaborations with multiple names in the grocery and retail sectors, including grocer ALDI, electronics company Best Buy, beauty retailer Sephora, and even Dollar Tree.Earlier this week, the company also announced weekly offers on groceries through the Fresh Days program, which is available to customers in the U.S., Canada, the U.K., South Africa, France, Japan, Taiwan, and Spain. For Fresh Days in the U.S., Uber One members will get 30% off every Tuesday on select fresh produce, meats, dairy, and eggs.Uber stock is up 62% this year and approximately 27% over the past 12 months.&nbsp;Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">directly on Stocktwits.</a>

An Uber Eats courier rides a bicycle through the streets of Amsterdam, Netherlands, on September 10, 2025. The rider carries a large green delivery bag. (Photo by Michael Nguyen/NurPhoto via Getty Images)

Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected

Bloomberg reported on Friday, citing a company spokesperson, that Uber expects grocery and retail deliveries to hit an annual run rate of $12.5 billion in gross bookings by the end of 2025.

Activist hedge fund Engine Capital is reportedly pushing Acadia Healthcare (ACHC) to refresh its board as it faces multiple federal investigations.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e96d221b-c275-4b3e-86aa-250f784d55dc">report</a> by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board of directors, and the halting of capital-intensive projects for new facilities.Acadia provides for-profit behavioral healthcare services. It is currently facing probes from the Department of Justice and Securities and Exchange Commission over allegations of holding patients against their will and falsifying insurance claims, the report noted.Shares of the company rose over 8% on Wednesday morning following the news. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHC">ACHC</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Tennessee-headquartered Acadia operated a network of 274 behavioral healthcare facilities, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics, with approximately 12,100 beds in 39 states and Puerto Rico as of the end of June. The company estimates that it serves more than 82,000 patients daily.As per FT, Engine Capital accused Acadia of maintaining a “growth at any cost” approach in its letter. It alleged that the approach has given rise to a bloated corporate structure and noted that a 2022 reorganisation left the company with an unwieldy management structure that has stifled the company’s turnaround.The firm also urged the company to add new directors with experience in behavioral health and capital allocation, while noting that the current board has no director with relevant operating experience. The hedge fund also encouraged the company to consider selling its assets and repurchasing shares.ACHC stock is down 40% this year and approximately 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an Acadia Healthcare logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp

According to a report by The Financial Times, the fund has written a letter to the company's board, requesting a review of its asset portfolio and improvements to its board.

According to a report by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board, and the halting of capital-intensive projects for new facilities.

Several firms increased their price target on Ionis Pharmaceuticals (IONS) on Tuesday after the company announced positive results from a study of its Zilganersen drug in children and adults living with a rare neurological condition called Alexander disease (AxD).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study">announced</a> on Tuesday that in the study, Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of the primary endpoint, gait speed, at week 61 compared to the control arm, with a favorable safety and tolerability profile. The company also said that Zilganersen indicated evidence of slowed disease progression, stabilization, or improvement.The firm intends to submit a new drug application to the U.S. Food and Drug Administration in the first quarter (Q1) of 2026. According to Ionis, Alexander Disease affects approximately one in one to three million people worldwide and has no approved disease-modifying treatments. The disease is characterized by progressive neurological deterioration, resulting in loss of functional mobility, independence, and the inability to control muscles for large movements, swallowing, and airway protection.Guggenheim on Tuesday raised its price target on the stock to $92 from $90, while maintaining a ‘Buy’ rating on the shares, according to TheFly. The new price target implies an upside of about 50% from the stock’s closing price on Monday.Other firms also hiked their price targets:<ol><li>Bank of America hiked its price target on IONS to $83 from $81 with a ‘Buy’ rating, while terming the news “an incremental positive” as Ionis could add another product to its expanding commercial portfolio.&nbsp;</li><li>Morgan Stanley hiked its price target on IONS to $86 from $71 while keeping an ‘Overweight’ rating on the shares.</li><li>Barclays also raised its price target on IONS to $80 from $78, with an ‘Overweight’ rating. The study results create a high probability of FDA approval, the analyst said.</li></ol>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IONS">IONS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:574/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_11_39_52_AM_png_6ae39ea7d7.webp" alt="IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="574" height="63"><figcaption>IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>IONS' stock is up 80% this year and approximately 50% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-ford-bronco-vehicles-after-recent-recall/chDhCRLR35q">US Regulator Closes Probe Into Ford Bronco Vehicles – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 

Shares of Scholar Rock (SRRK) rose about 2% on Tuesday morning after falling 12% in the pre-market session after the U.S. Food and Drug Administration refused to approve its Apitegromab drug for the treatment of patients with spinal muscular atrophy (SMA).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.scholarrock.com/news-releases/news-release-details/fda-issues-complete-response-letter-crl-apitegromab-treatment">stated</a> that the FDA raised concerns identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility. The agency did not make any observations specific to its drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data, the company said.Catalent Indiana was acquired by Danish drugmaker Novo Nordisk (NVO) in December. The facility submitted a response in early August 2025 to address the observations noted by the FDA and has continued to take corrective actions, the company said.Scholar Rock said it will resubmit its application for Apitegromab once Catalent Indiana’s issues with the FDA are resolved. The company stated that it believes the FDA will be able to act expeditiously on the application once the manufacturing issues have been resolved. “We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA (application) as soon as possible,” said CEO David L Hallal.Scholar Rock has also submitted Apitegromab for approval by the European Medicines Agency, and a decision is anticipated near mid-2026, the company said. It expects a European launch for the drug in the second half of 2026, starting with Germany.Scholar Rock believes Apitegromab may lead to a clinically meaningful improvement in motor function in patients with Spinal Muscular Atrophy (SMA), a rare, severe, genetic neuromuscular disease characterized by motor function decline.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_9_42_28_AM_png_308ee0f990.webp" alt="SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SRRK's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>Scholar Rock is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, Regeneron (REGN) <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">announced</a> that the FDA had extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions due to issues identified at the facility. &nbsp;SRRK stock is down 23% this year but up approximately 282% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q">Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

The company stated that the FDA did not make any observations specific to the drug or cite any other approvability concerns, including any pertaining to Apitegromab’s efficacy and safety data. 

Moderna (MRNA) said on Tuesday that its 2025-2026 formula of mNEXSPIKE demonstrated a strong immune response in recipients in a study.The updated formulation targets the LP.8.1 variant of the COVID-19-causing virus. Data from an ongoing phase 4, post-marketing study showed that the updated formula of mNEXSPIKE, on average, demonstrated a greater than 16-fold increase in neutralizing antibodies against the LP.8.1 variant, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6125971827149873&amp;symbol=MRNA">said</a>.A robust immune response was identified in individuals aged 12 to 64 years with at least one underlying condition that puts them at high risk for severe outcomes from an infection, as well as in all adults aged 65 years and older, the company added. The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> rose over 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around MRNA stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Moderna stated that the safety profile of the vaccine in the study was consistent with that observed in previous studies. mNEXSPIKE received the approval of the U.S. Food and Drug Administration in late May.Earlier this month, the company also announced that the 2025-2026 formula of its other COVID-19 vaccine, Spikevax, showed, on average, a greater than 8-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals participating in a Phase 4 study.Spikevax is approved by the FDA for individuals six months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE is only approved for individuals who are at least 12 years of age.MRNA stock is down 36% this year and approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rises-pre-market-after-ubs-raises-q3-delivery-estimate-mizuho-hikes-price-target/chDhMRBR35d">Tesla Stock Rises Pre-Market After UBS Raises Q3 Delivery Estimate, Mizuho Hikes Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study 

The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.

Oklo Inc. (OKLO) shares jumped 18% in early trading on Friday, with the ticker trending at the top spot on Stocktwits following the signing of the Technology Prosperity Deal by U.S. President Donald Trump and Prime Minister Keir Starmer a day earlier.&nbsp;The stock has been on an uptrend in recent times, gaining over 87% in the last month. On Friday, the stock hit a record high of over $124. The retail user message count on Oklo increased by 540% in the last 24 hours, as of Friday morning, on Stocktwits.On Thursday, the White House said that this deal would help build commercial partnerships to accelerate the deployment of advanced nuclear reactors in both the U.S. and the U.K.&nbsp;Retail sentiment on <a href="https://stocktwits.com/symbol/OKLO">Oklo</a> jumped to ‘extremely bullish’ territory from ‘bullish’ a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.The White House stated that the Technology Prosperity Deal supports the U.S. Nuclear Regulatory Commission, the UK Office for Nuclear Regulation, and the UK Environment Agency (EA) in streamlining and accelerating licensing. This effort aims to target reactor design reviews within two years and site licensing within one year.This comes on the heels of the U.S. Department of Energy reportedly calling on uranium producers to accelerate resource development in an effort to bolster nuclear power expansion.A bullish user on Stocktwits highlighted that they have recorded a 900% return so far.<a href="https://stocktwits.com/i_like_the_stock_meow/message/629290849">https://stocktwits.com/i_like_the_stock_meow/message/629290849</a>Shares of Oklo have gained nearly 480% this year and increased by 1,366% over the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-stock-nearly-doubled-in-a-month-just-received-a-price-target-hike-by-roth-capital/chD33nxR3TI">This Stock Nearly Doubled In A Month, And It Just Received A Fresh Price Target Hike By Roth Capital – Find Out More</a>

Oklo Stock Continues To Be The Talk Of The Town After Gaining 87% In A Month – Here’s How Retail Investors Responded

On Thursday, U.S. President Donald Trump and Prime Minister Keir Starmer signed the Technology Prosperity Deal, which included the deployment of new nuclear power stations.

Cracker Barrel Old Country Store (CBRL) shares declined 3% in early trading on Thursday after multiple Wall Street analysts trimmed their price target on the stock, noting a decline in traffic following the company’s controversial logo change in late August.Citigroup lowered the firm's price target on Cracker Barrel to $42 from $47 and maintained a ‘Sell’ rating, according to TheFly. The company reset fiscal 2026 expectations to well below estimates, acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.Cracker Barrel reverted to its old logo in August following a week-long controversy over its new logo that drew outrage from President Donald Trump as well. Last week, the company announced that it would suspend remodeling of restaurants to retain the “Old Timer” logo.Retail sentiment on <a href="https://stocktwits.com/symbol/CBRL">Cracker Barrel</a> dipped to ‘bearish’ from ‘bullish’ territory a day ago, with chatter at ‘high’ levels, according to data from Stocktwits. The retail message count also jumped nearly 500% over 24 hours as of Thursday morning on Stocktwits.<figure class="image"><img style="aspect-ratio:802/87;" src="https://news.stocktwits-cdn.com/CBRL_sentiment_png_30976da71f.webp" alt="CBRL sentiment .png" width="802" height="87"><figcaption>CBRL sentiment and message volume September 18, 2025, as of 10 am ET | Source: Stocktwits</figcaption></figure>Piper Sandler also cut its price target on Cracker Barrel to $49 from $56 and maintained a ‘Neutral’ rating, while Bank of America lowered its price target to $42 from $48 and maintained an ‘Underperform’ rating.Bank of America noted that stronger fiscal fourth-quarter restaurant comparable growth was "overshadowed by the recent uproar" around the company's logo change and store prototype test.CFO Craig Pommells said during the post-earnings call that traffic for the first half of August was down about 1%. Since August 19, the date of the initial logo change, traffic has declined approximately 8%.Cracker Barrel said that it expects fiscal 2026 total revenue to be between $3.35 billion and $3.45 billion, compared with estimates of $3.52 billion, according to data from Fiscal AI.Truist Securities trimmed its price target on Cracker Barrel to $58 from $62 and recommended a buy based on the weakness, citing its view that the core drivers of the brand's turnaround remain intact and that sales may start to recover from the rebranding and the resumption of Fall Menu marketing.Shares of Cracker Barrel have declined by nearly 7% and fallen 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ondas-stock-rising-today/chDcxyCR3bO">Why Is Ondas Stock Rising Today?</a>

A Cracker Barrel sign featuring the old logo hangs on the outside of a restaurant on August 21, 2025 in Homestead, Florida. (Photo by Joe Raedle/Getty Images)

Cracker Barrel In Spotlight After Slew Of Price Target Cuts: Citi Says Q1 Began In A ‘Deep Traffic Hole’ Post Logo Change

Citigroup lowered its price target on the stock to $42 from $47, noting that the company reset fiscal 2026 expectations well below estimates, while acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.

Duolingo (DUOL) shares were down nearly 4% in early trading on Wednesday, becoming the top trending ticker on Stocktwits after Citigroup lowered its price target on the stock to $375 from $400.Citigroup maintained a ‘Buy’ rating after attending the company’s annual global event Duocon 2025, according to TheFly. The firm believes that Duolingo's product announcements this year had a lower profile compared to past years.On Tuesday, Duolingo announced two major product updates at Duocon, primarily related to an integration that brings the Duolingo Score to LinkedIn Profiles, and the expansion of its Duolingo Chess course with an Android launch and a new player-versus-player mode on iOS.Retail sentiment on <a href="https://stocktwits.com/symbol/DUOL">Duolingo</a> improved to ‘bullish’ from ‘neutral’ territory a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:797/102;" src="https://news.stocktwits-cdn.com/DUOL_sentiment_png_d242d7e2c6.webp" alt="DUOL sentiment.png" width="797" height="102"><figcaption>DUOL sentiment and message volume September 17, 2025, as of 10:15 am ET | Source: Stocktwits</figcaption></figure>A user on Stocktwits noted that they were considering accumulating Duolingo stock.<stembedurl>https://stocktwits.com/ChrisChristopherson/message/628956384</stembedurl>Citigroup stated that the company continues to enhance its platform, which should help drive engagement; however, the firm has reduced its Duolingo user forecasts to reflect trends in third-party apps.In August, Duolingo beat its second-quarter results and raised its annual forecasts, driven by an increase in daily active users on the app.Separately, media reports noted that Hungary’s competition authority was investigating Duolingo regarding misleading claims about the effectiveness of its platform.Another user on Stocktwits noted that the stock was in a “great spot to buy.”&nbsp;Shares of Duolingo have declined over 16% this year but have gained 8% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-rejigs-ai-assistant-for-online-sellers-report/chDGpY8Rd6L">Amazon Rejigs AI Assistant For Online Sellers: Report</a>

A laptop keyboard and Duolingo on App Store displayed on a phone screen are seen in this illustration photo. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event

Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past.

RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite

Telsey Advisory Group stated that if an additional sector tariff on furniture is imposed, RH has the highest exposure within the home furnishings coverage group due to a high percentage of sales from furniture and limited sourcing in the U.S.

iShares Trust - iShares ESG Aware 60/40 Balanced Allocation ETF

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EAOR News

EAOR iShares ESG Aware 60/40 Balanced Allocation ETF